Literature DB >> 19812602

Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.

Patrick Terheyden, Roland Houben, Parisa Pajouh, Christoph Thorns, Detlef Zillikens, Jürgen C Becker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19812602     DOI： 10.1038/jid.2009.197

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  14 in total

Review 1.  [Treatment of advanced metastatic melanoma].

Authors:  S Ugurel; J C Becker
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

Review 2.  Melanoma: clinical features and genomic insights.

Authors:  Elena B Hawryluk; Hensin Tsao
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-02       Impact factor: 6.915

3.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

4.  Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor.

Authors:  Miki Itoh; Akira Goto; Hideki Wakasugi; Yutaka Yoshida; Yasutaka Matsunaga; Kenichi Fujii; Kazuya Suzuki; Kazuhiko Yonezawa; Takashi Abe; Yoshiaki Arimura; Yasuhisa Shinomura
Journal:  Int J Clin Oncol       Date:  2010-11-11       Impact factor: 3.402

5.  Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients.

Authors:  Carmen Ruiz; Julia Li; Madelyn S Luttgen; Anand Kolatkar; Jude T Kendall; Edna Flores; Zheng Topp; Wolfram E Samlowski; Edward McClay; Kelly Bethel; Soldano Ferrone; James Hicks; Peter Kuhn
Journal:  Phys Biol       Date:  2015-01-09       Impact factor: 2.583

6.  Phosphoproteomic screen identifies potential therapeutic targets in melanoma.

Authors:  Kathryn Tworkoski; Garima Singhal; Sebastian Szpakowski; Christina Ivins Zito; Antonella Bacchiocchi; Viswanathan Muthusamy; Marcus Bosenberg; Michael Krauthammer; Ruth Halaban; David F Stern
Journal:  Mol Cancer Res       Date:  2011-04-26       Impact factor: 5.852

Review 7.  Progressing Vulvar Melanoma Caused by Instability in cKIT Juxtamembrane Domain: A Case Report and Review of Literature.

Authors:  Monika Englert-Golon; Bartłomiej Budny; Małgorzata Lewandowska; Bartosz Burchardt; Natalia Smolarek; Katarzyna Ziemnicka; Paweł Piotr Jagodziński; Marek Ruchała; Marlena Grabowska; Stefan Sajdak
Journal:  Curr Oncol       Date:  2022-04-29       Impact factor: 3.109

Review 8.  Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Authors:  Catherine B Meador; Christine M Micheel; Mia A Levy; Christine M Lovly; Leora Horn; Jeremy L Warner; Douglas B Johnson; Zhongming Zhao; Ingrid A Anderson; Jeffrey A Sosman; Cindy L Vnencak-Jones; Kimberly B Dahlman; William Pao
Journal:  Clin Cancer Res       Date:  2014-03-05       Impact factor: 12.531

9.  Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.

Authors:  K Sakaizawa; Y Goto; Y Kiniwa; A Uchiyama; K Harada; S Shimada; T Saida; S Ferrone; M Takata; H Uhara; R Okuyama
Journal:  Br J Cancer       Date:  2012-01-26       Impact factor: 7.640

10.  Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.

Authors:  Christine M Lovly; Kimberly Brown Dahlman; Laurel E Fohn; Zengliu Su; Dora Dias-Santagata; Donna J Hicks; Donald Hucks; Elizabeth Berry; Charles Terry; MarKeesa Duke; Yingjun Su; Tammy Sobolik-Delmaire; Ann Richmond; Mark C Kelley; Cindy L Vnencak-Jones; A John Iafrate; Jeffrey Sosman; William Pao
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.